Boehringer In­gel­heim boosts R&D com­mit­ment, promis­es up to 15 new prod­uct launch­es by 2025

Com­ing off a strong year of growth for its Eli Lil­ly-part­nered SGLT2 in­hibitor Jar­diance, Boehringer In­gel­heim is putting those gains right back in­to R&D — and set­ting some lofty goals for the next few years.

The Ger­man com­pa­ny spent near­ly $4.5 bil­lion (20% of net sales) on R&D last year, putting it just be­hind some of the phar­ma in­dus­try’s top spenders. And over the next five years, it plans on sink­ing more than $27 bil­lion in­to drug de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.